Podcasts about Bayer

Despite appointing Robert F. Kennedy Jr. to bring his MAHA sensibilities to the administration, Donald Trump recently issued an executive order supporting domestic production of cancer-causing glyphosate and effectively shielding manufacturers like Bayer from state-level lawsuits while keeping the U.S. food system dependent on the herbicide.  Jimmy contrasts RFK's past legal battles against Monsanto/Bayer with his current defense of the policy, framing it as a reversal allegedly driven by "national security" concerns about Chinese supply chains but actually about that old stalwart: money.  Joe Rogan's podcast RFK claimed that banning glyphosate would disrupt corn and soy production in the U.S., but critics argue there is no serious transition plan toward regenerative or alternative farming methods. Jimmy concludes the segment by determining that RFK should resign rather than go along any more with this corrosive hypocrisy. Plus segments on Bill Clinton's literally unbelievable testimony about Jeffrey Epstein and Dan Bongino's latest unhinged attack on Candace Owens. Also featuring Stef Zamorano and Mike MacRae. And a phone call from JD Vance!

You might forgive Pollux if it feels disrespected. It’s the brightest star of Gemini – twice as bright as Castor, its “twin.” But the designation that’s most often used by astronomers is Beta Geminorum. And the Greek letter “Beta” usually is applied to a constellation’s runner-up. That naming system was created by German astronomer Johann Bayer, in 1603. He used the Greek alphabet to name most of the stars in a constellation. Usually, the brightest star was given the first letter, Alpha. The next-brightest was Beta, and so on. But in some cases, Bayer switched things up. He labeled the stars based on their location in the constellation’s classical outline, or on some other category. So for Gemini, Pollux became the “Beta” star even though it’s clearly brighter than “Alpha.” Pollux really is an impressive star. It’s moved into the red-giant phase of life. In fact, it’s the closest red giant to the Sun, at a distance of just 34 light-years. It’s puffed up to about nine times the diameter of the Sun, so it shines almost 40 times brighter than the Sun. And it has a distinctively orange tint – a beautiful look for an impressive star. Pollux and Castor line up to the upper left of the Moon at nightfall this evening. Pollux is closer to the Moon. The planet Jupiter is farther to the upper right of the Moon. Jupiter outshines all the true stars in the night sky – even the brightest light of Gemini. Script by Damond Benningfield

Joining me once again is Stephanie Seneff PhD, here today to discuss Donald Trump's recent Executive Order regarding glyphosate. Stephanie is an expert on the topic of glyphosate and has been on the cutting edge of its research for well over a decade. Today we discuss the many and varied dangers that this chemical poses, the illusion of higher crop yields pushed by the industry, and the synergistic way in which glyphosate works to destroy our health.  !function(r,u,m,b,l,e){r._Rumble=b,r[b]||(r[b]=function(){(r[b]._=r[b]._||[]).push(arguments);if(r[b]._.length==1){l=u.createElement(m),e=u.getElementsByTagName(m)[0],l.async=1,l.src="https://rumble.com/embedJS/u2q643"+(arguments[1].video?'.'+arguments[1].video:'')+"/?url="+encodeURIComponent(location.href)+"&args="+encodeURIComponent(JSON.stringify([].slice.apply(arguments))),e.parentNode.insertBefore(l,e)}})}(window, document, "script", "Rumble");   Rumble("play", {"video":"v746q8e","div":"rumble_v746q8e"}); Source Links: Home - Stephanie Seneff(15) Stephanie Seneff (@stephanieseneff) / X (21) Farm Action on X: "Trump 2024: “We're going to get toxic chemicals out of our food supply” Trump 2026: “Glyphosate is critical to national security” A new Executive Order doubles down on the same system that bankrupted farmers, monopolized the food supply under the control of a few multinational https://t.co/q5WBKpqOeE" / X Promoting the National Defense by Ensuring an Adequate Supply of Elemental Phosphorus and Glyphosate-Based Herbicides – The White House (21) Stephanie Seneff on X: "The Bayer lobbying empire. "Taken together, these relationships describe a network of aligned actors positioned across the American institutions that write the rules for pesticides, enforce those rules, and defend them in court." https://t.co/1dymzM59Ki" / X Tracing Bayer's ties to power in Trump's Washington New Tab (21) healthbot on X: "RFK Jr. talks about why gluten allergies have skyrocketed since 2006: "We discovered that Roundup was a desiccant. And what that means, if you spray it on a crop, it will actually dry out the crop. And one of the big enemies of the farmer is that if there's rain around the time https://t.co/tb9YTSgVmO" / X New Tab Stephanie Seneff/Denis Rancourt Roundtable - Glyphosate, mRNA & Spike Proteins Destroying Your Body Glyphosate's Onslaught on Akkermansia - The GUT CLUB Screen Shot 2026-02-27 at 11.25.19 AM.png (1872×944) (21) Grok / X New Tab Glyphosate Use in Crop Systems: Risks to Health and Sustainable Alternatives - PMC failure-to-yield.pdf Full article: Sustainability and innovation in staple crop production in the US Midwest Glyphosate-Resistant Soybean Cultivar Yields Compared with Sister Lines New Tab (21) MAHA Action on X: "“This is why I was put on this earth.” Surgeon General nominee Casey Means says she will focus on preventive care and real food to improve Americans' health. “My vision for Surgeon General and for the future of America is to get more healthy whole food on Americans' plates.” https://t.co/3YDDFg4cGZ" / X (21) The Last American Vagabond on X: "Yet here she is gaslighting us into thinking that Trump's EO leaning into glyphosate use and production is actually a planned roll back: https://t.co/5yxZSkbVeg" / X (21) Rob Schneider

Is the release of files on Project Artichoke a joke, mockery, or part of a plan to deconstruct the state? While parroting patriots brag about Olympic gold medals, the White House is at work gutting the tenth amendment, first over artificial intelligence, and now over glyphosate and agricultural chemicals.The release of files on 9/11, JFK, RFK, MLK, Epstein, etc., have vindicated as many conspiracy theories. But much of what was learned by some had already been known by others. Other files have not been released, or conspiracies exposed, like Project Artichoke or Northwoods. A new document pertaining to Artichoke was added to a CIA archive recently but the program has been known about since the 1970s. Nothing new has been released on Northwoods, yet the paper circulated as if it had been in 2025. DOGE exposed waste, but this was not the first time that has happened. Former FBI officials saying phones can be used to spy or influencers pointing out that many foods are food-like substances are both old news. The public is being fed already available information laced with poison. The goal appears to be the undermining of what little faith remains in all foundational, legacy systems. People then demand new parties and system of government. This is where Curtis Yarvin, Elon Musk, Peter Thiel, and JD Vance, among others, come into play. Their neoreactionary movement advocates for exposing flaws in the current system - failed democracy and bloated bureaucracies - to replace them with technological-monarchy and autocracy. A great example of how this is being done can be found in the issue of glyphosate. In Dec 2025: USDA announces $12 Billion to help farmers pay for chemicals/fertilizer. On Jan 2026: USDA releases the Pesticide Data Program report declaring 99% of food "safe” based on a USDA benchmark. On Feb 2026: Trump uses the Defense Production Act to label weedkiller a "national security asset." As with the Big Beautiful Bill, which was a massive and wasteful bill that stripped state-rights over Artificial Intelligence, HR 7567 is attempting to do the same with pesticide labeling. It calls for “uniformity in pesticide labeling nationally” and will “prohibit any State... or a court from directly or indirectly... hold[ing] liable any entity.” The bill effectively destroys the 10th amendment and state rights, setting an additional precedent for federal control. It's not just business as usual, it's worse business and it's worse than usual. The long declassified Project Artichoke, or the exploration of mind control, supposedly being to classified at the same time appears to be nothing more than a mockery and a joke.https://www.congress.gov/119/bills/hr7567/BILLS-119hr7567ih.pdfhttps://www.usda.gov/farmers-first https://www.ams.usda.gov/press-release/usda-publishes-2024-pesticide-data-program-annual-summaryhttps://www.whitehouse.gov/presidential-actions/2026/02/promoting-the-national-defense-by-ensuring-an-adequate-supply-of-elemental-phosphorus-and-glyphosate-based-herbicides/?utm_source=substack&utm_medium=email*The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.

Beim Antrittsbesuch in Peking hat Bundeskanzler Friedrich Merz einen versöhnlichen Ton angeschlagen: strategische Partnerschaft, kein Konfrontationskurs. Im Mittelpunkt des Besuchs stehen eindeutig die Wirtschaftsbeziehungen – Merz hat aber auch Chinas Einfluss auf Russland und den Krieg in der Ukraine angesprochen. Mit Kritik an seinen chinesischen Gastgebern hat sich Merz sehr zurückgehalten.[01:39]Direkt aus Peking berichtet Helene Bubrowski – und hat dort Bayer-CEO Bill Anderson getroffen, der mit der Wirtschaftsdelegation angereist ist. Bayer ist seit fast 150 Jahren in China aktiv und betreibt fünf Produktions- und fünf Innovationszentren. Anderson sieht China längst nicht mehr nur als Absatzmarkt, sondern als Forschungspartner – Decoupling hält er für den falschen Weg.[11:02]Zurück in Berlin: Michael Bröcker hat mit Esra Limbacher gesprochen, dem Sprecher des Seeheimer Kreises. Der SPD-Fraktionsvize fordert einen echten Mentalitätswechsel: „Wir haben momentan ein System in Deutschland, das ist echt stark auf Kontrolle und Berichtspflichten ausgelegt. Da müssen wir einen Wechsel hinbekommen und sagen: Ich vertraue als Staat Bürgern und Unternehmen – und misstraue nicht in erster Linie." Die bisherigen Reformvorschläge aus der Union nennt Limbacher Stückwerk.[14:29]Hier geht es zur Anmeldung für den Space.TableTable Briefings - For better informed decisions.Sie entscheiden besser, weil Sie besser informiert sind – das ist das Ziel von Table.Briefings. Wir verschaffen Ihnen mit jedem Professional Briefing, mit jeder Analyse und mit jedem Hintergrundstück einen Informationsvorsprung, am besten sogar einen Wettbewerbsvorteil. Table.Briefings bietet „Deep Journalism“, wir verbinden den Qualitätsanspruch von Leitmedien mit der Tiefenschärfe von Fachinformationen. Professional Briefings kostenlos kennenlernen: table.media/testenHier geht es zu unseren WerbepartnernImpressum: https://table.media/impressumDatenschutz: https://table.media/datenschutzerklaerungBei Interesse an Audio-Werbung in diesem Podcast melden Sie sich gerne bei Laurence Donath: laurence.donath@table.media Hosted on Acast. See acast.com/privacy for more information.

Renue Healthcare https://Renue.Healthcare/Todd Your journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.com Be confident in your portfolio with Bulwark! Schedule your free Know Your Risk Portfolio review. Go to KnowYourRiskPodcast.com today. Alan's Soaps https://www.AlansArtisanSoaps.com Use coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/Todd Get the new limited release, The Sisterhood, created to honor the extraordinary women behind the heroes. Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeWearing Jesus as a Costume: Jimmy Talarico // Trading Jesus for DJT // “Pastor” of 120,000 People Brags About Firing FolksEpisode links:First of all, Jesus was a craftsman, not unemployed. Second, this is Satan wearing a Christian cloak.@JamesTalarico: For 50 years, the religious right convinced our fellow Christians that the most important issues were abortion and gay marriage—two issues that aren't mentioned in the Bible. Pivoting to the God ThingBeware of false prophets, which come to you in sheep's clothing, but inwardly they are ravening wolves. Ye shall know them by their fruits." - Matthew 7 : 15-16 -- "The closest thing we have to the kingdom of heaven is a multiracial, multicultural democracy where power is truly shared among all people" - James TalaricoI HAD to makew sure this was an actual tweet. It is. This is real.  - Trump's appointee to be Ambassador to Maylasia Americans need to know: our government is under siege by lobbyists from German company Bayer.Bayer has spent over $9 million lobbying for exemption from liability for harm its chemicals like glyphosate might cause. The Constitution guarantees a trial for those who are harmed.SA megachurch pastor At Boshoff, who oversees 90 multisites and 120,000 members, demonstrates monstrously paranoid, narcissistic and controlling behavior, including firing a man who opened a meeting by saying "we are here for Jesus, we are not here to serve a man" because Boshoff believes he is to be served. Notably, despite Boshoff saying he'd get rid of anyone who speaks negatively against his wife, he actually divorced her a few years later, in secret, and never told the church about it until it was exposed more than a year later.South African megachurch Pastor At Boshoff divorces wife after more than 30 years of marriage

Welcome to The Daily Wrap Up, an in-depth investigatory show dedicated to bringing you the most relevant independent news, as we see it, from the last 24 hours (2/25/26). As always, take the information discussed in the video below and research it for yourself, and come to your own conclusions. Anyone telling you what the truth is, or claiming they have the answer, is likely leading you astray, for one reason or another. Stay Vigilant. !function(r,u,m,b,l,e){r._Rumble=b,r[b]||(r[b]=function(){(r[b]._=r[b]._||[]).push(arguments);if(r[b]._.length==1){l=u.createElement(m),e=u.getElementsByTagName(m)[0],l.async=1,l.src="https://rumble.com/embedJS/u2q643"+(arguments[1].video?'.'+arguments[1].video:'')+"/?url="+encodeURIComponent(location.href)+"&args="+encodeURIComponent(JSON.stringify([].slice.apply(arguments))),e.parentNode.insertBefore(l,e)}})}(window, document, "script", "Rumble");   Rumble("play", {"video":"v743gv6","div":"rumble_v743gv6"}); Video Source Links (In Chronological Order): (14) The Last American Vagabond on X: "Go ahead Mike, just say it.. “most important election of our lifetimes”

Nick begins a series of shows devoted to Vanessa Bayer, one of the most consistently funny cast members Saturday Night Live ever had. He talks a bit about her real-life story, including surviving cancer as a kid, and how that strength and optimism seemed to carry into her work on the show. He spends this hour revisiting Laura Parsons, the relentlessly upbeat child performer who somehow finds pure joy in acting out scenes from Brokeback Mountain and The Wolf of Wall Street. The joke never gets old because Bayer commits completely, smiling her way through material that no kid should be that excited about. Her Weekend Update bits are just as strong, especially when she's reporting on wildly inappropriate topics with total innocence. Guest appearances from Lady Gaga and Scarlett Johansson add to the chaos, and Michael Che trying to keep things under control on Update makes it even better. It's a funny, affectionate look at one great character and a reminder of why Vanessa Bayer's run on SNL was so special. [Ep 164]

APAC stocks traded higher as the region took impetus from the rebound on Wall Street after Anthropic's presentation helped soothe some AI/software concerns, and with tech also bolstered by the USD 60bln Meta-AMD chip deal; Euro Stoxx 50 futures up 0.2% after the cash market closed flat on Tuesday.US President Trump talked up the economy in his State of the Union Address, saying that the nation is back, bigger, better and stronger than before, while he added that we've seen nothing yet.Regarding tariffs, Trump said the Supreme Court decision on tariffs is very unfortunate but added that tariffs will remain in place and nearly all countries want to keep the trade deals.Trump also commented on Iran, which he claimed is working on missiles that could soon reach the US, and noted Iran wants to make a deal but hasn't yet said that it won't pursue nuclear weapons.Antipodeans were firmer amid the positive risk appetite, and with AUD/USD leading the advances following firmer-than-expected monthly CPI data from Australia.Looking ahead, highlights include German GfK (Mar), GDP Final (Q4), Swiss Sentiment (Feb), EZ HICP Final (Jan). Speakers include RBA's Bullock, Fed's Musalem, Barkin & Schmid. Supply from Germany & US. Earnings from NVIDIA, Salesforce, Snowflake, TJX Companies, Lowe's, Synopsys & Bayer.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Crash oder Rally: Der Dax kämpft mit der Marke von 25.000 Punkten. Da er schon länger praktisch seitwärts läuft, erwarten Experten einen starken Ausbruch. Aber was heißt das jetzt für Anleger? „An der Börse sind oft die Grautöne entscheidend. Für den Dax spricht seine zyklische Komponente. In den Schwellenländern geht die Post ab, in Deutschland nicht. Man kann auch sagen stabile Seitenlage für den Dax. In Amerika wird das Wirtschaftswachstum noch in der zweiten Jahreshälfte stärker werden", so Robert Halver. Wo sieht der Kapitalmarktexperte von der Baader Bank die Chancen für Anleger? Alle Details im Interview von Inside Wirtschaft-Chefredakteur Manuel Koch an der Frankfurter Börse und auf https://inside-wirtschaft.de

Audio roundup of selected biopharma industry content from Scrip over the business week ended February 20, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Hudson's legacy at Sanofi; the realities behind Trump's US pharma investment push; Bayer's precision medicine approach and growth; clinical trials to look out for this year; and Scrip Asks on AI and operational excellence. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-GO7ZGTBFEJDA5OUKAXHCTBVBDU/ Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Bayer Leverkusen hat es mit einem glanzlosen 0:0 im Rückspiel gegen Olympiakos ins Achtelfinale der Champions League geschafft. Dahin will auch der BVB, die Dortmunder müssen sich aber aus mehreren Gründen auf einen heißen Tanz in Italien einstellen.

It seems like every year there's a new disease infecting our crops here in Wisconsin and most recently for corn we've been seeing an increase in southern rust. Ashley Madson, a technical agronomist with Bayer, is here to share a bit of the history of this disease within Wisconsin and some tips for the 2026 season on choosing the right seed and best input management.See omnystudio.com/listener for privacy information.

Hey guys, this we are playing around with a live stream format to talk about news, shoot the crap, and just have a fun time hanging out. Let us know what you enjoy, what we could do different and what you would like to see in the future!Produced by Atlas AG Media Solutions:https://www.atlasmediagroup.usJohn Deere X9 1100 Mid Season Review:https://youtu.be/xf43fPK0jFgFind Neil on Instagram:https://www.instagram.com/neil_denton_farms/Follow Clayton:https://www.instagram.com/clayton.atlas/

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über Trumps Netflix-Forderung, Angst vor einem historischen Cut bei OpenAI und was sonst noch wichtig wird in dieser Woche. Außerdem geht es um Netflix, BASF, Bayer, Evonik, Amazon, Microsoft, Anthropic, Nvidia, Crowdstrike, Cloudflare, TEQ - Disruptive Technologies (WKN: DNA10X), TEQ - General Artificial Intelligence ETF (WKN: A41AXG), Xtrackers Artificial Intelligence & Big Data (WKN: A2N6LC), Invesco EQQQ Nasdaq 100 ETF (WKN: 801498), Caterpillar, AMD, ASML, TSMC, Trane Technologies, Dycom Industries, Vertiv, Eaton, SentinelOne, Lumentum und MongoDB. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Bundeskanzler Merz reist vom 24. bis 27. Februar nach China. Mit dabei eine große Wirtschaftsdelegation mit vielen wichtigen CEOs von Adidas, Bayer, Henkel, BMW, Mercedes, Volkswagen, der Commerzbank und vielen anderen Konzernen. Dahinter stecken natürlich viele Interessen - auch Rohstoffe spielen eine große Rolle. „Tendenziell bin ich ein Freund davon, dass man miteinander spricht statt beleidigte Leberwurst zu spielen. Gerade das Thema Rohstoffe ist ein enorm wichtiges Thema. Da hat China im letzten Jahr schon mal die Daumenschrauben gezeigt. Wir sind - das kann man nicht leugnen - in einem recht hohen Maße abhängig davon, dass wir aus China Rohstoffe wie seltene Erden importieren können. Deswegen ist diese Reise enorm wichtig", erklärt Michael Blumenroth im Rohstoff-Talk. Der Rohstoffanalyst der Deutschen Bank über den Gold- und Silberpreis nach dem großen Knall: „Wir hatten eine Beschleunigung Ende Januar gesehen, die völlig überzeichnet gewesen ist. Auch in Silber irrsinnig der Preis. Dann kam diese Korrektur. Die Problematik war gewesen, dass viele Händler nicht mit diesen hohen Preisen gerechnet hatten. Viele Optionen sind da in Schieflage geraten. Mittel- bis langfristig sehe ich für Gold Potenzial. Alles spricht weiterhin für den Goldpreis. Auf kurze Sicht könnten wir immer mal Rückschläge sehen. Wir haben unsere Prognose auf 6.000 Dollar je Unze bis Jahresende angehoben. Der Investment-Case für Gold ist da." Alle Details gibt es im Interview von Inside Wirtschaft-Chefredakteur Manuel Koch an der Frankfurter Börse und auf https://www.xetra-gold.com

--{ "Will the Real Rulers of America Please Stand Up?"}-- A few thoughts about religion and the individual - Bayer and Roundup lawsuits - Donald Trump's recent executive order, glyphosates, RFK Jr. and MAHA - What should we consider when reading coverage of the Epstein files? - Why now has the Overton Window shifted to encourage discussion of Jews and Israel in ways that were previously not allowed? - Trilateral Commission, RIIA, CFR - Orwell's Inner and Outer parties - Monsanto was presented as a solution; GMO - Trusting media to tell you what is right, wrong, true or false - Socialis is the totally scientific control of everyone on the planet from birth to death - We gave our manufacturing to China - Climate Change - George W. Bush was surrounded by Neocons - Agenda 21, 2030 - The destruction of common culture, religion, family - Are you ready for 6G? - 5G for surveillance; AI and the Internet of Things - The Guardian goes Orwell on Climate - Bezmenov: your money spent on useless, ridiculous projects - Green, and sustainable.

Sermon delivered on the First Sunday of Lent, 2026, in Harrisburg, Pennsylvania, by Rev. Tobias Bayer. Epistle: 2 Cor. 6, 1-10. Gospel: St. Matthew 4, 1-11.

With tighter margins, higher interest rates, and ongoing volatility, many producers are under pressure to make smart financial decisions. On this Ohio Ag Net Podcast, Nathaniel Watts, Head of Ag Retail Credit with Farm Credit Mid-America discusses a new campaign designed to help farmers turn financial statements into practical tools for planning, managing risk and building stronger operations. Plus, A new statewide initiative, the Ohio Farm Transition Network (OFTN), has officially launched operations to address one of the most pressing challenges facing Ohio agriculture: helping farm families successfully plan for the transition of their farms to the next generation. We talk with Ohio State Farm Management Specialist David Marrison about why a project like this is so important to rural Ohio. Then, Bayer's research agronomist Brian Dresbach talks with Ohio Ag Net's Joe Everett about some of the findings in 2025 research plots that will be helping farmers make sound planting decisions this season on the Ohio Ag Net Podcast, powered by Ohio Corn and Wheat.

Handel on the Law. Marginal Legal Advice.See omnystudio.com/listener for privacy information.

Handel on the Law. Marginal Legal Advice.See omnystudio.com/listener for privacy information.

Most household names with global brands are not the dividend growth stocks you think they are. They're thriving at selling products, but many struggle to pay shareholders, and some are closer to dividend cuts than you realise.In this episode, we peel back the curtain on giants likeBayer, Lyondell Basel, and Diageo. We reveal the red flags lurking behind their glossy veneer — from debt overreach and cyclical downturns to reckless acquisitions and questionable dividend sustainability. You'll discover why Bayer's disastrous Monsanto mergerturned into a debt nightmare, how cyclical industries can turn dividend darlings into ticking time bombs, and what the real danger signs are that a household name might cut its Dividend next year.

In this February 20 episode of MAHA News, Jordan Sather and Nate Prince break down the controversy surrounding the new executive order addressing glyphosate and elemental phosphorus under the Defense Production Act. They examine claims about immunity for Bayer, clarify what the order actually does, and discuss why glyphosate has become so embedded in the U.S. food system that an immediate ban could devastate farmers and spike food prices. The hosts reference Sri Lanka's failed nationwide organic experiment, RFK Jr.'s comments calling America's food system “chemical warfare,” and the broader tension between reform and food security. They also expose the flaws in the GRAS system, which allows food companies to self-certify ingredients as safe, and highlight alarming obesity and malnutrition trends in the U.S. Finally, they address the rapidly aging farmer population, rising farm bankruptcies, and structural issues making agriculture less viable for the next generation.

Ist Trumps Zoll-Hammer endgültig gestoppt? Die beiden Wirtschaftsjournalisten Dietmar Deffner & Holger Zschäpitz analysieren die Folgen für die Märkte nach dem Urteil des Supreme Court. Während die Aktienkurse jubeln, zittern die Anleihenmärkte vor einem 129-Milliarden-Dollar-Loch im US-Haushalt. Was heißt das für Europa, China & Co. – und welche „Plan B“-Hebel bleiben Trump noch? Außerdem geht es um Rheinmetall als „Freedom Tech“-Bulle, Bayer als Streitfall rund um Glyphosat, plus ein Ausblick auf die kommende Börsenwoche mit Ifo Index, Nvidia und wichtigen Zahlen von KI-Verlierern. DEFFNER & ZSCHÄPITZ sind wie das wahre Leben. Wie Optimist und Pessimist. Im wöchentlichen WELT-Podcast diskutieren und streiten die Journalisten Dietmar Deffner und Holger Zschäpitz über die wichtigen Wirtschaftsthemen des Alltags. Schreiben Sie uns an: wirtschaftspodcast@welt.de Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutzerklärung: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Der US-Präsident hat Glyphosat per Verordnung einen Sonderstatus gewährt. Die Verfügbarkeit des Herbizids sei unerlässlich. Hersteller Bayer begrüßte den Schritt.

Die Stimmung für die deutsche Wirtschaft hat sich diese Woche weiter eingetrübt, doch das Handelsvolumen an der Börse ist aktuell recht hoch. Welche Aktien und Branchen sind jetzt interessant? „Wenn man auf dem Rosenmontagszug ist und die Persiflage-Wagen sieht, wo die Politik durch den Kakao gezogen wird, dann weiß man, was auf den Nägeln brennt. Wir bekommen es nicht hin, weil wir keine knallharten Reformen machen. Nur Geld reinzupumpen, bringt ja nichts. Die Union hat Angst, an die AfD zu verlieren und die SPD an die Linken. Wäre die deutsche Politik an der Börse notiert, wäre sie ein Pennystock", so Robert Halver (Baader Bank). Für die aktuelle Situation gibt Jens Chrzanowski (Deutschlandchef vom Online-Broker XTB) klare Empfehlungen: „Wirtschaft und Börse sind öfter mal getrennt. Wir haben seit drei Jahren kein wirkliches Wachstum. Ganz schön schlechte Zeiten. Trotzdem sind wir nah am Allzeithoch. Die Stimmung ist weiterhin gut. Deutschland und die Welt haben Kapital. Handelsvolumen kann ja bedeuten, dass ich kaufe oder verkaufe. Ich hab mich im November festgelegt, was ich für 2026 auf meine Watchlist packe. Das sind drei deutsche Werte: Lufthansa, Bayer und Mercedes. Lufthansa seit Jahresbeginn elf Prozent im Plus, Bayer 23 Prozent im Plus, Noch nicht ganz so performt hat mein dritter Wert: Mercedes - im Minus mit 2,5 Prozent seit Jahresbeginn." Alle Details im Interview von Inside Wirtschaft-Chefredakteur Manuel Koch an der Frankfurter Börse und auf https://www.xtb.com

Nestlé, Air Liquide, Moncler y Bayer, bajo la lupa de Xavier Brun, responsable de RV de Trea AM.

Sermon delivered on Quinquagesima Sunday, 2026, in Richmond, Texas, by Rev. Tobias Bayer. Epistle: 1 Cor. 13, 1-13. Gospel: St. Luke 18, 31-43.

Leverkusen steht mit einem Bein im Champions-League-Achtelfinale, schlägt Piräus mit 2:0. Interessant: Bayer hat sich bei Leon Goretzka nach einem möglichen Wechsel erkundigt. Inter Mailand droht dagegen nach einer überraschenden Pleite das Aus. Ebenfalls Thema: die anderen Königsklassen-Spiele und die Europa-League-Partie vom VfB Stuttgart bei Celtic Glasgow. _Betonter Text_- [Instagram](https://www.instagram.com/stammplatz.pod/) - Stammplatz-Handy: 015165587282 - E-Mail: stammplatz@bild.de - Adresse: Stammplatz, André Albers, Noah Friedmann und Niklas Heising, Axel-Springer-Straße 65, 10888 Berlin Der tägliche Fußball-Podcast mit André Albers, Noah Friedmann und Niklas Heising! Stammplatz erscheint jeden Tag, wirklich JEDEN Tag! Wer hier zuhört, gibt beim Thema Fußball immer den Ton an! Stammplatz – tägliche Fußball-News

Tras una semana de parón por un muy buen motivo, volvemos a la rutina y lo hacemos con el Radiojaputa 266. Empezamos el podcast de esta semana con un capítulo de la historia de España muy silenciado: la Gran Redada Gitana, que es como se conoce al intento de genocidio del pueblo gitano por parte de los Borbones. Seguimos con vuestros mensajes. En esta ocasión, hablamos de la Tertulia Feminista Les Comadres, histórica asociación asturiana que cada año entrega los Premios Comadre de Oro, y que este año ha premiado a Barbijaputa en la categoría de activismo y comunicación, ocasión que nuestra amiga, directora de Radiojaputa, rompedora de familias, madre de feminazis y señora de los comunismos, ha aprovechado para salir ya del todo del anonimato acudiendo a recoger el premio en persona. También explicamos qué es eso del Premio Felpeyu y por qué este año ha recaído en Bayer y su lamentable anuncio en el que habla del olor de nuestras vaginas. La ética a la hora de invertir, el Caso Epstein y la necesidad de compartir y organizarnos, son otros de los temas que tratamos esta semana y que no te puedes perder. En la sección de hoy nos visita Belisa García, que viene con la sección “Yo no soy esa” bajo el brazo para hablarnos de una realidad dura y, cómo no, invisibilizada: violencia sexual hacia las mujeres y niñas con discapacidad y cómo se las gasta la justicia en estos casos. Cerramos con un audio de buen rollo, con la música de Marisa Valle Roso (¡otra de las Comadres de Oro 2026!), con agradecimiento y con la promesa de escucharnos muy pronto, como siempre, en este bote salvavidas.. a la deriva feminista. Para matrocinar este espacio, puedes hacerlo en radiojaputa.com. Si tú también quieres participar, mándanos un audio de whatsapp al (+34) 636 75 14 20. Y si te han gustado las canciones, las tienes todas en Youtube, listadas por temporadas.

Host: Rick Grobbee Guest: Annemien van den Bosch Want to watch that extended interview on Atrial septal defects in adults, go to: https://esc365.escardio.org/event/2552?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/2552 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel and Annemien van den Bosch have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Nando Sommerfeldt über einen möglichen Machtwechsel bei der EZB, starke Zahlen eines britischen Rüstungsriesen und ein letztes Ausrufezeichen von Warren Buffett. Außerdem geht es um Rheinmetall, Renk, Hensoldt, BAE Systems, Infineon, Analog Devices, Bayer, Berkshire Hathaway, New York Times, Carvana, Doordash, Ebay, Garmin, RTL Group, Evonik, Volkswagen, Porsche, Vonovia, BMW, Mercedes, Allianz, Deutsche Telekom, Siemens und Tesla. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

This episode covers: Cardiology This Week: A concise summary of recent studies Atrial septal defects in adults Conservative and invasive management of chronic coronary syndromes Milestones: 4S trial   Host: Rick Grobbee Guests: JP Carpenter, Annemien van den Bosch, Rasha Al-Lamee, Roxana Mehran Want to watch the episode? Go to: https://esc365.escardio.org/event/2552 Want to watch the extended interview on Atrial septal defects in adults, go to: https://esc365.escardio.org/event/2552?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel and Annemien van den Bosch have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Roxana Mehran has declared to have potential conflicts of interest to report: institutional research payments from Abbott, Alleviant Medical, Chiesi, Concept Medical, Cordis, CPC Clinical Research, Daiichi Sankyo, Duke, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Medtronic, NewAmsterdam Pharma, Novartis, Novo Nordisk Inc., Population Health Research Institute (PHRI), Protembis GmbH, Radcliffe, RM Global Bioaccess Fund Management, Sanofi US Services, Inc. ; personal fees from: None ; Equity

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a wide array of topics, from groundbreaking therapies and strategic corporate moves to regulatory shifts and industry trends shaping the future of healthcare.We begin with Eli Lilly, which is making significant strides with its combined Zepbound and Taltz therapy, showing promising results in the treatment of psoriasis and obesity. This combination therapy, initially successful in psoriatic arthritis, is set to transform treatment protocols by bridging gaps between psoriasis and obesity. This dual-targeting approach highlights a burgeoning trend in the industry: the use of combination therapies to enhance patient outcomes while streamlining treatment regimens. This strategy not only promises better management of interconnected conditions but also reflects a broader industry goal of maximizing therapeutic reach with existing drugs.Novartis is advancing its portfolio with the oral BTK inhibitor, Rhapsido, following a successful Phase 3 trial for a new chronic hives subtype. This development underscores Novartis's commitment to addressing niche markets and unmet medical needs, emphasizing the pharmaceutical industry's focus on expanding the utility of existing drugs. Additionally, Novartis has entered into a notable partnership with Macrocycle Biotech for cardiovascular drug development. This collaboration represents a broader trend where large pharmaceutical companies seek innovative partnerships to expand their therapeutic portfolios through cutting-edge biotech solutions.Meanwhile, Moderna's influenza vaccine submission has been accepted by the FDA after an initial rejection, illustrating a responsive regulatory environment crucial for timely access to vaccines amid potential flu outbreaks.Johnson & Johnson's $1 billion investment plan in the U.S., focusing on cell therapy, aligns with broader industry trends towards personalized medicine and advanced therapeutic approaches. This investment is part of a strategic pivot towards cell and gene therapies that promise to redefine treatment pathways for complex diseases. Similarly, Bayer's $7.25 billion settlement over Roundup litigation shows an industry keen on resolving legal challenges swiftly to refocus efforts on innovation.Regulatory reforms are also gaining attention, with proposals aimed at streamlining FDA processes to enhance drug access and reduce burdens. These reforms could significantly impact drug development timelines and market entry strategies, reflecting an ongoing discourse on balancing regulation with fostering innovation.On a global scale, Stada's €85 million investment in Saudi Arabia points to a strategic move towards enhancing supply chain resilience in the Middle East and North Africa. This aligns with industry trends focusing on regional manufacturing capabilities to ensure drug availability while reducing logistical complexities.A notable example of strategic resource allocation is Eli Lilly's $100 million upfront payment for CSL's IL-6 antibody development rights. This reflects an adaptive approach where initial clinical setbacks are seen as opportunities for new therapeutic ventures rather than dead ends.Turning our attention to Alzheimer's research, Korsana Biosciences has emerged from stealth mode with substantial funding aimed at developing an anti-amyloid antibody capable of crossing the blood-brain barrier. This effort addresses a critical need within Alzheimer's disease treatment—a field marked by intense competition and scientific challenge. Parallelly, IQVIA Biotech highlights the importance of accelerating early-stage interventions for Alzheimer's through data analytics and optimized clinical trials. Such efforts aim to expedite regulatory approvals and bring new therapies to market faster—a trend indicative of leveragSupport the show

From the BBC World Service: Japan's export figures were the strongest in three years, climbing 16.8% year over year in January. The data sharply beat market expectations. Plus, the German drugs giant Bayer is offering to pay more than $10 billion to settle claims over the weedkiller Roundup. And, European commercial flights have resumed to Venezuela for the first time since the ousting of President Nicolás Maduro.

From the BBC World Service: Japan's export figures were the strongest in three years, climbing 16.8% year over year in January. The data sharply beat market expectations. Plus, the German drugs giant Bayer is offering to pay more than $10 billion to settle claims over the weedkiller Roundup. And, European commercial flights have resumed to Venezuela for the first time since the ousting of President Nicolás Maduro.

With the European Union launching a formal investigation into fast fashion giant Shein over the Chinese business' possible breaches of digital law, we hear from Thomas Regnier on what the EU Commission's concerns are. Andrew Peach speaks to Oscar-winning film and TV producer Tom Nunan on the latest in Netflix and Paramount's tug-of-war over Warner Bros. Elsewhere, German drugs giant Bayer proposes to pay more than US$7.25bn (£5.35bn) to settle claims that its weedkiller Roundup causes cancer. And Iran closes the Strait of Hormuz for military drills... but will it affect global oil prices? The latest business and finance news from around the world, on the BBC. (Picture: People walk past a Shein pop-up store at immersive retail space Future Stores, ahead of its grand opening in London, Great Britain, on 24 September, 2025. Credit: Isabel Infantes / Reuters.)

Dan Buck fills in for Marc Cox, opening Hour 2 with breaking news on the deadly California avalanche and the stalled Guthrie case dominating headlines despite lack of new info. Coverage shifts to international focus with Iran nuclear negotiations and commentary on AOC and Hillary Clinton's support of the EU Digital Services Act. Nicole Murray reports on major business developments from Bayer, Amazon, Tesla, Google, Warner Bros., and Meta, while the “In Other News” segment touches on Olympic antics, Costco app upgrades, Buffalo Wild Wings, and $672M lost to online romance scams. The hour blends hard news, business updates, and quirky human-interest stories for a comprehensive morning briefing. Hashtags: #CaliforniaAvalanche #GuthrieCase #IranNuclearTalks #NicoleMurray #InOtherNews #Olympics2026 #BusinessNews #ConsumerNews

This Day in Legal History: Aaron Burr Arrested (But Not For That)On February 18, 1807, former Vice President Aaron Burr was arrested in the Mississippi Territory on charges of treason against the United States. Once one of the most powerful men in the young republic, Burr had fallen from political grace after killing Alexander Hamilton in a duel and drifting to the margins of national life. Federal authorities accused him of plotting to carve out an independent nation in the western territories, possibly including lands belonging to Spain. The allegations sparked fear that the fragile Union could splinter only decades after independence.Later that year, Burr stood trial in Richmond, Virginia, before Chief Justice John Marshall, who was riding circuit. The case quickly became a constitutional showdown between executive power and judicial restraint. President Thomas Jefferson strongly supported the prosecution, but Marshall insisted that the Constitution's Treason Clause be applied strictly. The Constitution requires proof of an “overt act” of levying war against the United States, not merely evidence of intent or conspiracy.Marshall ruled that prosecutors had failed to present sufficient proof that Burr had committed such an overt act. As a result, the jury acquitted him. The decision established an enduring precedent that treason must be narrowly defined and carefully proven. By demanding clear evidence of action rather than suspicion or political hostility, the court reinforced limits on the government's power to punish alleged disloyalty. Burr's trial remains one of the earliest and most significant tests of constitutional safeguards in American legal history.Bayer AG and its Monsanto subsidiary have proposed a $7.25 billion nationwide class settlement to resolve current and future claims that Roundup exposure caused non-Hodgkin lymphoma. Filed in Missouri state court, the agreement would run for up to 21 years and provide capped, declining annual payments. People diagnosed before or within 16 years after final court approval could seek compensation through the program. The settlement must still receive judicial approval.The proposal is part of a broader strategy tied to the U.S. Supreme Court's pending review of Durnell v. Monsanto, which could determine whether federal pesticide labeling law blocks certain state failure-to-warn claims. Bayer has indicated that a favorable ruling could significantly limit future lawsuits, while the class program is designed to address claims regardless of the Court's decision. Plaintiffs' attorneys say the deal would cover both occupational and residential exposure and protect the rights of future claimants, while allowing individuals to opt out and pursue separate suits.Roundup litigation has generated tens of thousands of cases, with more than 40,000 already pending or subject to tolling agreements. Bayer inherited the legal challenges after acquiring Monsanto in 2018, and the ongoing litigation has weighed heavily on the company financially and reputationally. Previous jury verdicts have resulted in multibillion-dollar awards, some later reduced on appeal or by judges. The new proposal would replace an earlier settlement effort that collapsed in 2020 and aims to create a longer-term, more predictable compensation system.Bayer AG Unveils $7.3B Deal For Roundup Users - Law360Bayer proposes $7.25 billion plan to settle Roundup cancer cases | ReutersA Seattle federal jury found inventor Leigh Rothschild, several of his patent-holding companies, and his former attorney liable for violating Washington's anti-patent trolling law after asserting patent infringement claims against Valve Corp. Jurors concluded the defendants acted in bad faith under the Washington Patent Troll Prevention Act and also violated the state's consumer protection statute. Valve was awarded $22,092 in statutory damages.The jury also determined that Rothschild and his companies breached a 2016 global settlement and licensing agreement with Valve. Under that agreement, Valve paid $130,000 for rights to certain patents in exchange for a promise not to sue over them. Despite that covenant, Rothschild's entities later filed a 2022 infringement lawsuit and sent a 2023 letter threatening additional litigation. The jury awarded Valve $130,000 for the first breach and $1 for the second, finding no valid justification for repudiating the agreement.In addition, jurors ruled that one asserted patent claim was invalid because it would have been obvious to a skilled professional at the time of filing. The dispute stemmed from Valve's 2023 lawsuit accusing Rothschild of repeatedly pursuing claims covered by the prior settlement. The defense argued any mistakes were unintentional and not profit-driven, but the jury sided with Valve after a four-day trial.The case also involved procedural controversies, including sanctions over delayed financial disclosures and allegations that a defense filing contained fabricated quotations and citations generated by artificial intelligence. Post-trial motions are expected as the defense challenges aspects of the verdict.Valve Jury Says Rothschild, Atty Broke Anti-Patent Troll Law - Law360Beginning July 1, 2026, new federal limits will cap loans for professional degree students at $50,000 per year and $200,000 total, significantly changing how aspiring lawyers finance law school. Administrators and financial aid experts warn that the cap may push students to rely on private loans, which often carry higher interest rates and fewer protections. Unlike federal loans, private loans are generally not eligible for Public Service Loan Forgiveness, making them riskier for students planning lower-paying public interest careers.Some admitted students are already reconsidering their options, choosing less expensive schools or withdrawing altogether after calculating potential debt burdens. Law schools may need to increase scholarships or other aid to support students who cannot secure private loans. Private lending has been minimal in legal education since 2006, when federal policy allowed graduate students to borrow up to the full cost of attendance, so there is uncertainty about how lenders will respond to renewed demand.Data show that about one-quarter of ABA-accredited law schools currently have average annual federal borrowing above the new $50,000 cap. At some elite institutions, graduates tend to earn high salaries, which may reassure private lenders. However, other schools with high borrowing levels report much lower median earnings, raising concerns about repayment risks. Experts warn that students at lower-ranked schools or from disadvantaged backgrounds could be hit hardest.In response, some schools are creating new financial strategies. The University of Kansas School of Law has launched an in-house loan program with a fixed 5% interest rate for borrowing above the cap. Santa Clara University School of Law is offering guaranteed scholarships to reduce tuition below the federal limit, and applications there have surged. Overall, the loan cap introduces financial uncertainty that could reshape enrollment decisions, access to legal education, and the long-term cost of becoming a lawyer.US law schools, students fear rising costs from new federal loan cap | ReutersThe U.S. Supreme Court has introduced new software designed to help identify potential conflicts of interest involving the justices. The tool will compare information about parties and attorneys in pending cases with financial and other disclosures maintained by each justice's chambers. These automated checks are intended to supplement, not replace, the justices' existing internal review process when deciding whether to step aside from a case.Under current practice, each of the nine justices independently determines whether recusal is necessary. The move comes after the Court adopted its first formal code of conduct in 2023, which states that a justice should withdraw when their impartiality could reasonably be questioned. Critics have pointed out that the code lacks an enforcement mechanism and leaves recusal decisions solely in the hands of the justices themselves.To support the new system, the Court is also strengthening filing requirements. Parties will need to provide more detailed disclosures, including fuller lists of involved entities and relevant stock ticker symbols. These updated requirements will take effect on March 16. Advocacy groups welcomed the technological upgrade as a step toward better ethics oversight, noting that similar conflict-checking systems have long been standard in lower federal courts.US Supreme Court adopts new technology to help identify conflicts of interest | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

We are live at the A.I. Impact summit in New Delhi where Mistral CEO Arthur Mensch tells CNBC that a large proportion of enterprise software could end up heavily disrupted by artificial intelligence. German chemicals giant Bayer settles a $7.25bn litigation deal regarding of thousands of lawsuits over the roundup weedkiller. The agreement has pushed shares up by more than 7 per cent at yesterday's market close in Europe. The Reform UK party is to launch its plans for the OBR and the BoE later today but the central bank's independence is not up for discussion.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Nach Monaten des Rückzugs verzeichnet die ukrainische Armee Geländegewinne. Hat Milliardär Musk mit der Starlink-Abschaltung für Russland eine Wende im Krieg ausgelöst? Zweifel bleiben.

Michael Calhoun visits with CBS legal analyst Thane Rosenbaum as Bayer is working toward a $7.25 billion settlement over future claims that its Roundup weed killer causes cancer. Rosenbaum says Bayer is hedging its bets ahead of a possible Supreme Court ruling that could wipe out previous settlements.

Mutmaßlicher IT-Angriff auf Deutsche Bahn: Wie Info- und Ticketsystem lahmgelegt wurden. Ukraine-Gespräche in Genf beendet: Ein diplomatischer Fortschritt? Einigung im Glyphosat-Rechtsstreit: Was der "Monsanto-Deal" für Bayer und seine Aktionäre bringt. Moderation: Johannes Döbbelt Von WDR 5.

Sturmberg, Jessica www.deutschlandfunk.de, Wirtschaft und Gesellschaft

Bei unserem Partner Scalable Capital gibt's jetzt nicht nur das unserer Meinung nach beste Broker-Angebot in Deutschland. Ihr kriegt auch noch 25 € vom Scalable-ETF, wenn ihr ein neues Konto eröffnet und nutzt. Dazu unterstützt ihr auch noch diesen Podcast. Mehr Infos gibt's hier. Aktivisten stürmen die Börsen: Elliott x Norwegian Cruise Lines, Starboard x TripAdvisor, Jana x Fiserv. Infleqtion-IPO, Raspberry Pi als KI-Geheimtipp, Compass Pathways mit Psilocybin. Warner Bros. x Paramount, Masimo x Danaher. ServiceNow x Management. Hat Bayer (WKN: BAY001) gestern die Lösung der Glyphosat-Krise gefunden? Und wieso steigt die Aktie immer weiter? Wir klären auf. Das ganze Interview mit Bill Anderson zum Bayer-Turnaround findet ihr hier: https://www.youtube.com/watch?v=tAxTJCDPQ08. Diesen Podcast vom 18.02.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Bayer announced a proposed multi-billion dollar settlement between its indirect subsidiary Monsanto and plaintiffs alleging exposure to Roundup caused cancer. The settlement was filed today in the Circuit Court of the City of St. Louis. The USDA today announced proposed updates to federal line speed regulations in poultry and pork establishments operating under modern inspection systems. CoBank expects fewer acres planted to corn and more to soybeans in the U.S. this year. 

The makers of Roundup close in on a legal settlement for thousands of pending lawsuits. AP correspondent Jennifer King reports.

Great to be back after a day away for President's Day. First up this evening a story about companied raising prices. Why? Think Trump Tariffs.  This is the Business News Headlines for Tuesday the 17th day of February, thanks for listening. . In other news, Warner Brothers and Paramount back in the news. Bayer and the 7.25 billion dollar settlement hit today.  France and India get together for talks…think economics and trade. The Epstein Files takes down another and we'll share that story.  We will also check the numbers in The Wall Street Report and get this…television viewing has increased in the U.S.  What about streaming?  We'll share that story as well.  Let's go. Thanks for listening! The award winning Insight on Business the News Hour with Michael Libbie is the only weekday business news podcast in the Midwest. The national, regional and some local business news along with long-form business interviews can be heard Monday - Friday. You can subscribe on  PlayerFM, Podbean, iTunes, Spotify, Stitcher or TuneIn Radio. And you can catch The Business News Hour Week in Review each Sunday Noon Central on News/Talk 1540 KXEL. The Business News Hour is a production of Insight Advertising, Marketing & Communications. You can follow us on Twitter @IoB_NewsHour...and on Threads @Insight_On_Business.

Will Linssen has been ranked as World's # 1 Leadership Coach by Global Gurus (USA) and recognized as #1 Coach Trainer by Thinkers50 (UK). Furthermore, Will is a Master Certified Coach at the International Coaching Federation (ICF) and co-author of the Marshall Goldsmith Stakeholder Centered Coaching methodology. For over two decades he has been working with executive teams to measurably improve their leadership and team effectiveness. He has held several positions in general management and business management at multinational companies in Europe, North America, and Asia and he has served at the board of several multinationals in Asia. Will travels the globe training executive coaches and coaching business leaders using GCG's highly effective methodology. Clients consistently commend his results-driven personality combined with his confident, energetic, and relatable style. A good listener and problem solver with in-depth business knowledge and cross-cultural understanding, he has been recognized for his creative and analytical skills, and most of his executive clients hold international positions in a wide range of industries at Fortune 500 Cos across USA, LATAM, Europe, Asia, and Australia a.o. AON, Allianz, BAT, Bayer, Coca Cola, GSK, ING, Kimberly Clark, LG, LinkedIn, McDonalds, Novartis, Pepsi, Philips, Philip Morris, Sanofi, Standard Chartered Bank, Saudi Telecom, Saudi Institute of Public Administration, Syngenta, SC Johnson and Uber.More Info: Global Coach GroupSponsors: Become a Guest on Master Leadership Podcast: Book HereAgency Sponsorships: Book GuestsMaster Your Podcast Course: MasterYourSwagFree Coaching Session: Master Leadership 360 CoachingSupport this show http://supporter.acast.com/masterleadership. Hosted on Acast. See acast.com/privacy for more information.

Pod favorite Tommy Bayer returns and the boys have some BIG laughs. We talk about my upbringing as a serbian boy, why geese is a 6, my terrible green room hang, and my ocd it's truly a great ep once again....but was there audio issues? let me know!